RT Journal Article
SR Electronic
T1 Viable Monkeypox virus in the environment of a patient room
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.15.22280012
DO 10.1101/2022.09.15.22280012
A1 Marimuthu, Kalisvar
A1 Ching Wong, Judith Chui
A1 Lim, Poh Lian
A1 Octavia, Sophie
A1 Huan, Xiaowei
A1 Ng, Yi Kai
A1 Yang, Jun Jing
A1 Sutjipto, Stephanie
A1 Linn, Kyaw Zaw
A1 Setoh, Yin Xiang
A1 Ong, Chong Hui Clara
A1 Griffiths, Jane
A1 Farhanah, Sharifah
A1 Cheok, Thai Shawn
A1 Binti Sulaiman, Nur Ashikin
A1 Congcong, Sipaco Barbara
A1 Neves, Erica Sena
A1 Loo, Liang Hui
A1 Hakim, Luqman
A1 Sim, Shuzhen
A1 Lim, Merrill
A1 Nazeem, Mohammad
A1 Vasoo, Shawn
A1 Tham, Kwok Wai
A1 Ng, Oon Tek
A1 Ng, Lee Ching
YR 2022
UL http://medrxiv.org/content/early/2022/09/17/2022.09.15.22280012.abstract
AB We conducted a prospective environmental surveillance study to investigate the air, surface, dust and water contamination of a room occupied by a patient infected with Monkeypox virus (MPXV) at various stages of his illness. The patient tested positive for MPXV from a throat swab and skin lesions. Environmental sampling was conducted in a negative pressure room with 12 unidirectional HEPA air changes per hour and daily cleaning of the surfaces. A total of 179 environmental samples were collected on days 7, 8, 13, and 21 of his illness. Air, surface, and dust contamination was highest during the first eight days of the illness, with a gradual decline to the lowest contamination level by day 21. Viable MPXV was isolated from surfaces and dust samples and no viable virus was isolated from the air and water samples.Synopsis Inadequate research prevail on the mode of transmission for monkeypox virus. This study reports the findings of viable monkeypox virus from the patient environment, highlighting its implications for human health and impact on infection and prevention control measures.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research is supported by the Singapore Ministry of Health, National Medical Research Council under its NMRC Collaborative Grant Collaborative Solutions Targeting Antimicrobial Resistance Threats in Health Systems, NMRC Clinician Scientist Award and NMRC Clinician Scientist Individual Research Grant. The study is also internally funded by the National Environment Agency.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent was obtained from the patient as part of the PROTECT study protocol and Ethics committee of National Healthcare Group gave ethical approval for this work. This study was approved by the Environmental Health Institute Management Committee, Project TS325, National Environment Agency.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript